Menu Search
Equities

Kobayashi Pharmaceutical Co Ltd

KOY:DUS

Kobayashi Pharmaceutical Co Ltd

Actions
  • Price (EUR)34.00
  • Today's Change0.80 / 2.41%
  • Shares traded--
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 18:31 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year Kobayashi Pharmaceutical Co Ltd had little change in net income (from 20.02bn to 20.34bn) despite revenues that grew 4.33% from 166.26bn to 173.46bn. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 32.88% to 33.66%.
Gross margin54.72%
Net profit margin8.04%
Operating margin9.61%
Return on assets5.26%
Return on equity6.65%
Return on investment6.41%
More ▼

Cash flow in JPYView more

In 2023, cash reserves at Kobayashi Pharmaceutical Co Ltd fell by 19.79bn. However, the company earned 18.36bn from its operations for a Cash Flow Margin of 10.58%. In addition the company used 19.58bn on investing activities and also paid 19.46bn in financing cash flows.
Cash flow per share280.59
Price/Cash flow per share20.18
Book value per share2,821.32
Tangible book value per share2,518.57
More ▼

Balance sheet in JPYView more

Kobayashi Pharmaceutical Co Ltd has little financial risk as the capital structure does not rely on leverage.
Current ratio2.88
Quick ratio2.21
Total debt/total equity0.0055
Total debt/total capital0.0054
More ▼

Growth rates in JPY

SmartText is unavailable
Div yield(5 year avg)0.96%
Div growth rate (5 year)8.88%
Payout ratio (TTM)53.97%
EPS growth(5 years)3.30
EPS (TTM) vs
TTM 1 year ago		-30.12
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.